Paysign, Inc. (PAYS) Q2 2025 Earnings Call Transcript

Paysign (PAYS) reported a strong Q2 2025, achieving record revenue of $19.1 million, up 33% year-over-year, alongside significant profitability improvements including a 102% increase in adjusted EBITDA to $4.5 million and a 99% rise in net income to $1.4 million. This performance was primarily driven by its patient affordability business, which saw revenue surge 190% to $7.75 million, fueled by new program launches and proprietary dynamic business rules technology. Although plasma compensation revenue declined 4.7% year-over-year, sequential growth and the onboarding of 123 new centers are expected to return it to year-over-year growth, complemented by a new SaaS offering. Paysign raised its full-year 2025 revenue guidance to $76.5-$78.5 million, reflecting continued momentum and strategic investments in capacity, underscoring a positive outlook despite some segment-specific challenges.

Analysis

Paysign, Inc. (PAYS) reported a record-setting second quarter for 2025, demonstrating significant operational leverage and a strategic shift toward its high-growth patient affordability business. Total revenue increased 33% year-over-year to $19.1 million, while adjusted EBITDA doubled to $4.5 million, showcasing strong profitability despite absorbing $300,000 in one-time onboarding costs. The primary catalyst was the patient affordability segment, where revenue surged 190% YoY to $7.75 million, now accounting for 40.6% of total revenue compared to 18.7% in the prior year. This growth is underpinned by an 83% increase in revenue per program and an 80% rise in claims processed, driven by the adoption of its proprietary dynamic business rules technology. The company's program pipeline remains robust, with 30-40 new programs expected by year-end, supported by a planned fourfold expansion of its patient services contact center capacity. Conversely, the legacy plasma compensation business experienced a 4.7% YoY revenue decline to $10.7 million due to industry-wide headwinds from plasma oversupply. However, the segment grew 14.2% sequentially and is positioned for a return to YoY growth following the onboarding of 123 new centers, which increased its market share to approximately 50%. Management raised its full-year 2025 revenue guidance to a range of $76.5 million to $78.5 million and reaffirmed its adjusted EBITDA forecast of $18 million to $20 million, signaling confidence in the continued momentum of the patient affordability segment and the stabilization of the plasma business.

Key Decisions for Investors

• Investors should recognize the ongoing business model transformation, where the high-margin, rapidly expanding patient affordability segment (+190% YoY revenue) is becoming the primary value driver, mitigating weakness in the legacy plasma business.
• Monitor the plasma segment's return to year-over-year growth in the second half of 2025, as this is a key component of the updated guidance and depends on the successful integration of 132 newly acquired centers.
• Evaluate the company's ability to maintain its full-year gross profit margin guidance of 61-62% while absorbing costs from the new patient services contact center, as this will be a key test of operational efficiency amid rapid scaling.
• Consider the strategic pivot within the plasma business towards a SaaS model with its new donor management platform, as early adoption by plasma collectors could unlock a new, recurring revenue stream and expand the company's total addressable market.